Correlation Between SAB Biotherapeutics and Hookipa Pharma

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Hookipa Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Hookipa Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Hookipa Pharma, you can compare the effects of market volatilities on SAB Biotherapeutics and Hookipa Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Hookipa Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Hookipa Pharma.

Diversification Opportunities for SAB Biotherapeutics and Hookipa Pharma

0.7

Correlation Coefficient

SAB Biotherapeutics  Hookipa Pharma

Poor diversification

The 3 months correlation between SAB and Hookipa is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Hookipa Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hookipa Pharma and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Hookipa Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hookipa Pharma has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Hookipa Pharma go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Hookipa Pharma

Given the investment horizon of 90 days SAB Biotherapeutics is expected to under-perform the Hookipa Pharma. In addition to that, SAB Biotherapeutics is 1.69 times more volatile than Hookipa Pharma. It trades about -0.13 of its total potential returns per unit of risk. Hookipa Pharma is currently generating about -0.12 per unit of volatility. If you would invest  194.00  in Hookipa Pharma on December 27, 2024 and sell it today you would lose (71.00) from holding Hookipa Pharma or give up 36.6% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

SAB Biotherapeutics  vs.  Hookipa Pharma

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Hookipa Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with SAB Biotherapeutics and Hookipa Pharma

The main advantage of trading using opposite SAB Biotherapeutics and Hookipa Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Hookipa Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hookipa Pharma will offset losses from the drop in Hookipa Pharma's long position.

The idea behind SAB Biotherapeutics and Hookipa Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.